Abilify Maintena® (aripiprazole) – New indication
July 28, 2017 – Otsuka announced the FDA approval of Abilify Maintena (aripiprazole) extended-release injectable suspension, for maintenance monotherapy treatment of bipolar I disorder in adults.
Download PDF
